Add To Watchlist
Share URL
About The Company
Description
Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases.
Read More
Overview
Value
1
Growth
13
Health
25
Management
60
Analyst Opinion
63
Total
32
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- Has a high level of debt
- Does not hold enough liquid assets to cover short term liabilities
- Poor overall financial health
- No margin of safety at their current market price
- Poor earnings and cashflow growth 0
Market Peers
AMNI.ST
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-1128.99%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
-13.20%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0.1 SEK
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-507.45%
PE/Earnings Growth
N/A
Price/Book
6.04x
Growth
Growth Score
13
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of 7.05% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of -14.51% is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
7.05%
Cashflow Growth
-14.51%
Health
Health Score
25
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
10.16x
Current Assets/Liabilities
0.33x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
1.65x
Management
Management Score
60
Average Buybacks/Dilution
-13.20%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
54.01%
Return On Assets
-89.23%
Return On Capital Employed
-14.71%
Return On Equity
-1739.88%
Return On Free Cashflow
258.57%
Return On Investments
N/A
Analysts
Analyst Opinion
63
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Amniotics AB (publ)
Currency
SEK
Beta
0
Vol Avg
57150
Ceo
Mr. Kare Engkilde
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
21
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2021-07-06
Address
ScheelevAegen 2
City
Lund
State
Country
SE
Zip
22381
Phone
46 7 23 27 85 20
All financial data provided by FMP